Treatment of patients with severe autoimmune hepatitis

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 1, 2008, Pages 57-63

  Larsen, F S ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Azathioprine; Hepatitis, autoimmune; Liver failure; Mycophenolate mofetil; Prednisone; Tacrolimus

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

AUTOIMMUNE HEPATITIS; EDEMA; HEADACHE; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MONOTHERAPY; OPPORTUNISTIC INFECTION; REVIEW;

HEPATITIS, AUTOIMMUNE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 42049107493     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43(2 Suppl 1):S132-44.
2. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35:75-81.
3. Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 2000;31:1194-200.
4. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62.
5. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007;46:1138-45.
6. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007;4:202-14.
7. Kanzler S, Gerken G, Löhr H, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-5.
8. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
9. Czaja AJ, Freese DK; American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
10. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-85.
11. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitniçk GL, Elveback IR et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
12. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83.
13. Roberts SK, Therneua T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57.
14. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:646-52.
15. Larsen FS, Vainer B, Eefsen M, Bjemng PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6.
16. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
17. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003.
18. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006 5;354:54-66.
19. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13.
20. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
21. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516-22.
22. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
23. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007;5:799-802.
24. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15.
25. Alvarez F, Ciocca M, Cañero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
26. Soloway RD, Hewlett AT. The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: a concise review. Ann Hepatol 2007;6:204-7.
27. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
28. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. Clin Gastroenterol 2004;38:805-9.
29. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005;5:1085-9.
30. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376-7.